A merger between US-based healthcare conglomerate Baxter and Sweden-based medical technologies company Gambro will be cleared by the European Commission, say reports. The agreement, signed at $4 billion, was modified when Baxter agreed to divest part of the company worth about one-fifth of its annual turnover, said two unnamed sources. Clearance from the European Commission would make the company the second-largest dialysis equipment manufacturer; reports say the global market is set to grow as obesity and diabetes rates climb. The two companies announced the deal last December.
Featured News
New York Puts Businesses on Notice for Algorithmic Pricing
Mar 19, 2026 by
CPI
Herbert Smith Freehills Kramer Expands US Antitrust Team with New Partner Hire
Mar 19, 2026 by
CPI
Mexico Antitrust Authority Fines Oxygen Suppliers Over Exclusive Contracts
Mar 19, 2026 by
CPI
EU Cloud Group Pushes for Halt to Broadcom VMware Changes
Mar 19, 2026 by
CPI
Sen. Blackburn Releases Discussion Draft of Bill to Set Federal ‘Framework’ for AI Policy
Mar 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data-Driven Competition
Mar 19, 2026 by
CPI
Data-Driven Competition: Implications For Enforcement and Merger Control
Mar 19, 2026 by
Alexandre de Corniere & Greg Taylor
From Tipping to Trustees: Why Data-Driven Markets Require Institutional Design, Not Optimization
Mar 19, 2026 by
Jens Prüfer & Paul de Bijl
Data Barriers to Entry: What We’ve Learned About Spotting Them and What We Still Don’t Know About Solutions
Mar 19, 2026 by
Bruno Carballa-Smichowski
When the Perfect Is the Enemy of the Good: Price Discrimination, Affordability, Precarity and Market Dynamism
Mar 19, 2026 by
Dan Ciuriak